This Week in Addiction Medicine from ASAM

Lead Story: Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C

Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C
The American Journal of Drug and Alcohol Abuse
This qualitative analysis identified and categorized state MOUD-related statutes and regulations in a random sample of four geographic locations covering 16 states and Washington D.C. The policies that appear to expand MOUD access fall within six policy domains: 1) expanding the availability of waivered buprenorphine providers, 2) expanding MOUD awareness, 3) criminal justice, 4) licensed SUD facilities, 5) insurers, and 6) hospitals. Some states appear to have taken more substantial policy efforts than others toward MOUD expansion, rather than conducting needs assessments or expanding educational opportunities for patients/providers. The authors identified several frontiers where laws are changing in ways that could potentially translate to better access to care.
 
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM

Lead Story: Reducing Opioid Use Disorder and Overdose Deaths in the United States: A Dynamic Modeling Analysis

Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis  
Science Advances
Since 1999, nearly 650,000 Americans have died of an opioid overdose. More than half of these deaths have occurred since 2016 due to increasing misuse of prescription opioids, followed by heroin, and now synthetic opioids such as illicitly manufactured fentanyl. This study used a system dynamics simulation model of the US opioid-using population age 12 and older to explore the impacts of 11 strategies on the prevalence of opioid use disorder (OUD) and fatal opioid overdoses from 2022 to 2032. By 2032, three strategies saved the most lives: (i) reducing the risk of opioid overdose involving fentanyl use, which may be achieved through fentanyl-focused harm reduction services; (ii) increasing naloxone distribution to people who use opioids; and (iii) recovery support for people in remission, which reduced deaths by reducing OUD. 
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM

Lead Story: Long-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering

Long-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering 🔓
JAMA Network Open
In this cohort study, 19,377 patients experienced opioid dose tapering from 2008 to 2017; this, after a 12-month baseline period of stable daily dosing of 50 morphine milligram equivalents or higher. The authors hypothesized that tapered patients would have reduced rates of study outcomes during the postinduction period. However, rates of withdrawal, overdose, and mental health crises each increased significantly in the postinduction period. These findings suggest that elevated risks of overdose and mental health crisis may persist for up to 2 years after taper initiation. Patients prescribed higher doses may benefit from more intensive support and monitoring, particularly for depression and suicidality.
 
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM

Lead Story: HBCD Study Will Answer Important Questions about Substance Use in Pregnancy

Brain lesions disrupting addiction map to a common human brain circuit 🔓
Nature Medicine
In rare cases, regional brain damage can lead to addiction remission. These cases may be used to identify therapeutic targets for neuromodulation. This study analyzed two cohorts of patients addicted to smoking at the time of focal brain damage.  Associations with addiction remission were identified. Lesions disrupting smoking addiction occurred in many different brain locations but were characterized by a specific pattern of brain connectivity. This pattern involved positive connectivity to the dorsal cingulate, lateral prefrontal cortex, and insula and negative connectivity to the medial prefrontal and temporal cortex. This circuit was reproducible across independent lesion cohorts, associated with reduced alcohol addiction risk, and specific to addiction metrics. Hubs in this circuit provide testable targets for therapeutic neuromodulation.
 
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM

Lead Story: Modeling the Evolution of the US Opioid Crisis for National Policy Development

Lead Story: Modeling the Evolution of the US Opioid Crisis for National Policy Development 🔓
From: Proceedings of the National Academy of Sciences
Delays between enaction of policy and data about the impact of the policy on drug-use behavior, as well as the complexity of other factors that influence drug-use behaviors, can make policy decision making difficult. To assist policy makers, the authors created a model utilizing data between 1999 and 2020 to understand historical use patterns and to project future scenarios. In testing, the model was able to closely replicate historical trajectories and had good model fit for various scenarios. While the model has some limitations -- notably it does not address co-occurring stimulant use -- it does potentially provide a resource for policy makers in projecting future use patterns and policy analysis. 
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM

Lead Story: Daily E-cigarette Use and the Surge in JUUL Sales: 2017–2019

Show Notes for Tuesday, June 7, 2022
 
Lead Story: Daily E-cigarette Use and the Surge in JUUL Sales: 2017–2019 🔓
From: Pediatrics
This study identified how the 2017 rapid surge in sales of JUUL e-cigarettes affected usage among US youth and young adults.  For 5 age groups, it compared 2-year incidence of first tobacco use and of new-onset daily tobacco use by product, and report levels of dependence. Sociodemographic variables and rates of experimentation with any tobacco product were similar between cohorts. About 600 000 Americans aged

Lead Story: Getting to the Heart of Cannabis Health Risks

Getting to the Heart of Cannabis Health Risks
Cell Press
Cannabis has deleterious effects on cardiovascular physiology. Wei et al. (Cell 185, May 12, 2022) confirm that important inflammatory markers increase transiently after a single marijuana joint and prove a mechanistic link between THC induced vascular inflammation, endothelial dysfunction, cellular oxidative stress, and atherosclerosis using cell-based and mouse models of atherosclerosis. They provide a pharmacological model in which THC-mediated activation of CB1 receptor signaling pathways converge on MAP kinase, TNFa, and NF-kB outputs to create a proinflammatory and atherogenic environment in endothelial cells.   That genistein can antagonize the negative effects of THC with minimal central effects is exciting because genistein is a common component of soy and is already a widely consumed dietary product.
 
Electronic Cigarettes Versus Nicotine Patches for Smoking Cessation in Pregnancy: A Randomized Controlled Trial
Nature Medicine
Pregnant smokers were randomized to use either nicotine replacement therapy with patches (NRT, n=571) or e-cigarettes (n=569) for smoking cessation. For the primary outcome, validated prolonged quit rates at the end of pregnancy, the results were 4.4% for NRT and 6.8% for e-cigarettes (P=0.08). However, 25 participants in the NRT arm who reported abstinence also used e-cigarettes. When these participants were excluded from data analysis the quit rates were 3.6% for NRT and 6.8% for e-cigarettes (P=0.02). Low birthweight was less common in the e-cigarette arm, 9.6% versus 14.8% for NRT (P=0.01). The authors conclude that “e-cigarettes were markedly more effective than patches” and do not pose more risk.
 
Daily Cannabis Use, Cannabis Use Disorder, and Any Medical Cannabis Use Among US Adults: Associations Within Racial, Ethnic, and Sexual Minoritized Identities in a Changing Policy Context
Preventive Medicine Reports
Cannabis use has steadily increased in the United States, with daily and medical use associated with cannabis use disorder (CUD) and the negative consequences more frequent among marginalized groups. In this study, the authors use the National Survey on Drug Use and Health (NSDUH) to examine medical and daily use and CUD across the intersections of racial, ethnic, and sexual minorities. They found that sexual minorities were more likely to have medical and daily use and CUD than their heterosexual counterparts within each racial and ethnic group. However, when examining the intersection of race, ethnicity and sexual identity, there was more heterogeneity across these groups. In addition, they found that in states with medical cannabis laws (MCL) daily cannabis use was higher across all intersectional groups.  
 
Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial
AJP Psychiatry
Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder. In patients with major depression, dextromethorphan-bupropion (AXS-05) significantly improved depressive symptoms compared with bupropion and was generally well tolerated.  The most common adverse events were dizziness, nausea, dry mouth, decreased appetite, and anxiety. Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or sexual dysfunction.
 
Mental Health and Substance Use Among Homeless Adolescents in the US
JAMA Network
This study evaluated mental health and substance use outcomes among homeless and non-homeless adolescents in 2019. Alcohol, cigarette, marijuana, and binge drinking during the prior 30 days was assessed, along with lifetime use of cocaine, methamphetamine, heroin, ecstasy, and injection drugs or prescription opioid misuse. Results found current substance use ranging from cigarettes to alcohol were higher among homeless adolescents. Lifetime cocaine use was significantly higher among homeless adolescents, as were methamphetamine, heroin, ecstasy, and injection drug use. Homeless adolescents experience worse mental health outcomes, including depression and suicidality, and struggle with more SUDs than their counterparts.
 
The Importance of Federal Action Supporting Overdose-Prevention Centers
NEJM
In this prospective piece, the authors discuss the need for new approaches to harm reduction and substance use disorder treatment in the face of substantially increasing overdose deaths, particularly since the start of the COVID-19 pandemic. One such strategy they discuss is overdose-prevention centers, which operate in other countries and are associated with significant reductions in opioid-overdose morbidity and mortality. However, under Section 856 of the Controlled Substances Act, such facilities may be subject to federal legal sanctions. The authors recommend that the Biden administration declare they will not interfere with such public health interventions or declare that section 856 does not apply to legally sanctioned centers. Further, Congress should modify the Controlled Substance Act to exempt overdose-prevention centers. 
 
Complex Persistent Benzodiazepine Dependence—When Benzodiazepine Deprescribing Goes Awry
JAMA Psychiatry
Benzodiazepines remain popular medications among patients due to rapid symptom relief and reinforcing effects. As clinicians and patients become more aware of potential risks, and clinical guidelines increasingly urge caution in prescribing, guidance for benzodiazepine deprescribing is needed. The authors propose a new clinical concept for patients experiencing significant psychological or functional decline during or after a benzodiazepine taper—complex
persistent benzodiazepine dependence (CPBD). CPBD can be described as symptomatic or functional decompensation with or without the development of aberrant medication behaviors in the setting of benzodiazepine deprescribing–in the absence of a benzodiazepine use disorder. Further research is needed to validate this concept. 
 
What is Success in Treatment for Opioid Use Disorder? Perspectives of Physicians and Patients in Primary Care Settings
JSAT
Opioid abstinence and treatment retention are typically used as measures of success of MOUD treatment. This study sought to identify other important treatment outcomes and patient-centered measures of success. Qualitative, structured interviews were conducted with physicians (n=14)  and patients (n=18) in 2 family medicine residency programs. The physicians (7 faculty and 7 residents) were experienced buprenorphine prescribers. Both patients and physicians identified 5 themes: staying sober, and improvement in physical health, mental health, relationships, and role functioning. Patients, but not physicians, identified 2 additional themes: tapering off buprenorphine, and decreased stigma and shame. The authors conclude that “clinicians and researchers need to consider a broader scope of success indicators.”
 

Lead Story: Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use 🔓
JAMA Network Open
This comparative effectiveness study evaluated 179 280 individuals with opioid use disorder (OUD) using insurance claims. Individuals with OUD and co-occurring substance use disorders (SUDs) were less likely to receive buprenorphine and more likely to receive extended-release naltrexone than peers without polysubstance use; buprenorphine and extended-release naltrexone were comparable in their protective associations with drug- related poisonings in both populations. These findings suggest that individuals with co-occurring SUDs were less likely to receive buprenorphine despite buprenorphine’s association with protecting against overdose in this population.
 
Perceived effectiveness of objective elements of vaping prevention messages among adolescents 🔓
Tobacco Control
To date, no comprehensive analysis of vaping prevention message elements has been conducted. This study examined how objective features of vaping prevention messages predict adolescents’ perceptions of those messages. Items such as addiction, chemicals, and negative health symptoms/effects were associated with higher perceived message effectiveness (PME); the word ‘addiction’ was associated with higher PME only for non-users. Referencing lung effects increased PME for current users but not for non-users. Items such as industry targeting, environmental impact, and flavor themes were associated with lower PME, along with first-person language or the word ‘teen.’ Prevention messages that even moderately improve vaping-related outcomes have the potential to improve vaping prevention.
 
Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver 🔓
JAMA Network Open
As opioid-related deaths increase, methods to reduce barriers to prescribing buprenorphine are needed. What is unclear is whether removal of the X-waiver requirement for prescribing buprenorphine will be enough to increase access. This study was conducted to better understand key barriers/facilitators to prescribing beyond those related to the X-waiver process. A survey of Texas clinicians who received waiver training between March 2019 and February 2020 was distributed, with a follow-up survey later in the year assessing nine barriers to treatment. Complexity of X-waiver process, perceived lack of professional support and referral network, and getting started were found to be barriers to prescribing; supportive professional networks were a key facilitator. 
 
Prevalence and Correlates of Driving under the Influence of Stimulants: Evidence from a National Sample 
Addictive Behaviors
This study notes an increase in cocaine use over the last decade and even greater increase in the use of methamphetamine. Data on stimulant use and driving under the influence of stimulants (DUIS) was obtained from four years of the National Survey on Drug Use and Health (2016-2019). Among adults reporting stimulant use in the past year 28% reported DUIS and 56% for those who met DSM IV criteria for stimulant abuse/dependence. Odds of DUIS was lower among women (AOR 0.78). A majority of those reporting DUIS also reported driving under the influence of alcohol (53%) or cannabis (59%).  
 
Does it come from tobacco? Young adults’ interpretations of the term “tobacco-free nicotine” in a cross-sectional national survey sample 🔓
PLOS One
“Tobacco-free” nicotine (TFN) products are relatively new to the market. Although as of March 2022 they fall under FDA regulation as tobacco products, there is still concern about public understanding of these products and potential impact on nicotine product use, particularly among adolescents and young adults. In this study, the authors surveyed those 18-25 years of age to assess knowledge about tobacco products in general and TFN products in particular. Overall, young adults lack knowledge about nicotine-containing products, frequently incorrectly identifying the nicotine source for cigarettes (38.1%), smokeless tobacco (47.9%), e-cigarettes (53.4%) nicotine pouches (74.4%), and TFN (42.2%). Of particular concern, 17.1% of respondents believed TFN products did not contain nicotine or tobacco. FDA regulation around marketing of TFN products may be needed. 
 
Prevention, treatment and care of substance use disorders in times of COVID-19 🔓
World Psychiatry
In this editorial, The United Nations Office on Drugs and Crime (UNODC) – World Health Organization Informal Scientific Network (ISN) provides multiple recommendations for care of substance use disorders (SUDs). During the COVID-19 pandemic, persons with SUDs have fared worse than the general population, both in terms of risk of infection and worse outcomes with infection. One of the key public health principles is providing services to populations with increased vulnerabilities; this also benefits the entire population. Among the recommendations from the ISN are inclusion of mental health and SUD experts in COVID-19 task forces and development of strategies to ensure SUDs are treated like any other chronic medical condition during the pandemic and beyond. 
 
Can slogans prevent gambling harm?
The Lancet Public Health
This is a commentary on a study assessing the efficacy of a slogan used in a safer gambling campaign in the UK. The slogan “When the fun stops, stop” did not have the intended effect in this study of experienced gamblers. The author observes that a safer gambling campaign implies that there is a safe level of gambling which may not exist, for example with electronic gambling machines. A parallel is drawn with responsible drinking campaigns that have little impact on actual alcohol consumption. They also focus responsibility on the individual rather than providers and regulators. The author notes that experience with alcohol and tobacco has shown that advertising emphasizing the harms of use can discourage harmful use.  
 
The stigma of alcohol-related liver disease and its impact on healthcare 
Journal of Hepatology
This review summarizes the evidence on alcohol related liver disease (ALD) stigma in healthcare and its implications for people with ALD. Public stigma, self-stigma and structural stigma all contribute to increased illness burden of ALD, failure to or delay of seeking help, inferior healthcare, and negative health outcomes. Stigma can be experienced, but also anticipated and avoided, which all negatively impacts ALD healthcare. Blaming people with ALD for their condition is central to ALD stigma. Stigma affects ALD healthcare at all stages, from prevention, early detection and intervention, to allocation of scarce resources in liver transplantation. People with lived experience need to be empowered to lead action against the stigma of ALD.
 

Lead Story: Opioid and Naloxone Prescribing Following Insertion of Prompts in the Electronic Health Record to Encourage Compliance With California State Opioid Law

Opioid and Naloxone Prescribing Following Insertion of Prompts in the Electronic Health Record to Encourage Compliance With California State Opioid Law [OPEN ACCESS]
JAMA Network Open 
In 2018, California passed Assembly Bill (AB) 2760, mandating coprescription of naloxone and opioids for patients with high overdose risk. The current study assessed whether electronic prompts were associated with increased naloxone orders and reduced opioid prescribing when integrated into the practitioner workflow. Naloxone order rate increased from 2% in December 2018 to 13.2% in January 2019 and then continued to increase to 27.1% in December 2019. Outpatient opioid prescribing rates decreased by 15.1% per prescriber-month and total MMEs per prescriber-month decreased by 7.8%, along with other improvements in safe opioid prescribing. Adding decision support prompts to the practitioner workflow encourages safe prescribing habits and can mitigate opioid overdose risks.
 
Epidemiological trends in opioid-only and opioid/polysubstance-related death rates among American Indian/Alaska Native populations from 1999 to 2019: a retrospective longitudinal ecological study [OPEN ACCESS]
BMJ Open
Deaths due to overdoses have been increasing in the United States over the last 2 decades, but little is known about the epidemic among American Indian/Alaskan Native (AI/AN) populations. In this study the authors use the National Center for Health Statistics Mortality database to examine overdose deaths between 1999 and 2019. Overdose deaths related to opioids increased significantly over the observation period, including deaths involving other substances, notably alcohol and methamphetamines. Overall overdose mortality rates, and specifically those related to opioids in combination with alcohol or methamphetamines, have been higher among AI/AN than in other racial and ethnic groups. This study highlights inequities in access to treatment for AI/AN populations, including lack of access to medication assisted treatment for opioid use disorder. 
 
Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials [OPEN ACCESS]
International Journal of Environmental Research and Public Health
The authors identified 6 randomized clinical trials of buprenorphine efficacy and/or safety and performed a secondary analysis with lapse to substance use as the outcome variable. They developed a mathematical model to adjust for the effects of dose changes or missed doses during the study period (time-weighted dose). The 6 trials included 3022 participants. The mean (and median) dose was 12mg and ranged up to 32mg. Increased dose was found to be the most protective factor in preventing lapse to drug use. Also of benefit were increased interaction with clinicians and treatment center staff. The authors conclude that doses greater than that needed to prevent withdrawal are needed for maintenance treatment.  
 
Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study
The Journal of Clinical Psychiatry
This study examined the association between receiving antidepressants and retention in buprenorphine treatment. Receipt of antidepressants during buprenorphine treatment was significantly associated with reduced risk of treatment discontinuation, even after accounting for demographics, buprenorphine dosage, receipt of other psychotropic medications, co-occurring SUDs, psychiatric disorders, and pain conditions. Receiving antidepressants only prior to buprenorphine initiation was associated with an increased risk of treatment discontinuation. Using antidepressants concurrently during buprenorphine treatment is associated with improved treatment retention and highlights the importance of screening for and treating mental health disorders.
 
Delivering Remote Measurement-Based Care in Community Addiction Treatment: Engagement and Usability Over a 6-Month Clinical Pilot [OPEN ACCESS]
Frontiers in Psychiatry
Measurement-based care (MBC) is an evidence-based practice where patients routinely complete standardized measures throughout treatment to monitor clinical progress and inform clinical decision-making. This pilot study evaluated the feasibility of incorporating a digital and remotely delivered MBC system into substance use disorder (SUD) treatment within a community setting.  Patient and clinician ratings of usability and clinical utility were favorable: most patients agreed with statements that the weekly check-in was easy to navigate and aided self-reflection. All clinicians who completed usability questionnaires agreed with statements indicating that the dashboard was easy to navigate and that it provided meaningful information for SUD treatment.
 
Evaluation of Trends in Alcohol Use Disorder–Related Mortality in the US Before and During the COVID-19 Pandemic
JAMA Network Open
Alcohol sales and use have increased during the COVID-19 pandemic and in this cross-sectional study utilizing the National Vital Statistic System, the authors examine alcohol use disorder (AUD)-related mortality changes. The study looks at AUD-related mortality trends between 2012 and 2019 to project expected mortality in 2020 and 2021, which were then compared to the observed rates. The authors found a significant increase in mortality rates across all ages in 2020 (30.74%) and 2021 (28.7%) compared to projected rates. In addition, the study found the increase was most profound among those aged 25-44 (40.47% and 33.95% increases). Interventions to address the increase in AUD-related mortality should consider changes in use related to the pandemic. 
 
Wait No Longer: Reducing Medication Wait-Times for Individuals with Co-Occurring Disorders
Journal of Dual Diagnosis
Community addiction treatment agencies have utilized Network for the Improvement of Addiction Treatment (NIATx) to reduce appointment wait-times. This exploratory analysis evaluated the impact of the NIATx implementation strategies on reduced wait-times to addiction, psychotropic, or both medications for individuals with co-occurring disorders (COD).  NIATx implementation strategies reduced medication encounter wait-times but timing of agency improvements varied. Despite a significant improvement, a three-week wait-time to receive pharmacological interventions is suboptimal for those with a COD in need of immediate intervention. Community addiction treatment agencies should improve medication access so that their patients “wait no longer” to receive integrated treatment for their COD.
 
Prehospital Buprenorphine Treatment for Opioid Use Disorder by Paramedics: First Year Results of the EMS Buprenorphine Use Pilot [OPEN ACCESS]
Prehospital Emergency Care
This study describes a program allowing EMS personnel to administer buprenorphine in the field to patients experiencing withdrawal (COWS>7) under the supervision of an Emergency Physician. Initial doses of 16 mg were administered and an additional 8mg were provided if needed. Substance use navigators facilitated connection with treatment and followed patient outcomes. Over the one-year trial period, 36 patients received buprenorphine. Treatment retention at seven days was 50% and 36% at 30 days. The authors conclude that EMS administered buprenorphine is feasible, safe, and has significant treatment retention at 30 days.  

Lead Story: Association of Co-Prescribing of Opioid and Benzodiazepine Substitutes With Incident Falls and Fracture

Association of co-prescribing of opioid and benzodiazepine substitutes with incident falls and fractures among older adults: a cohort study [Open Access]
BMJ Open 
This study extracted data from Medicare records of 47,964 enrollees who were diagnosed with chronic pain and anxiety and prescribed some combination of the studied medications (opioids, benzodiazepines, gabapentinoids (GABA), or antidepressants  (SSRI/SNRI)). The outcome measure was falls or fractures. The authors note that prior research has shown opioids+benzodiazepines to be associated with high rates of falls, fractures, and deaths. These data show that opioids+GABA was associated with a greater risk of falls and fractures than opioids+benzodiazepines. An even greater risk of falls was associated with use of three or more of these medications. The authors conclude that clinicians may be underestimating the sedating effects of gabapentinoids.  
 
Stimulant-related incident surveillance using emergency medical service records in Massachusetts, 2013–2020
Drug and Alcohol Dependence
Rates of stimulant use and stimulant use disorder (StUD) have been steadily increasing, as have overdoses with stimulant use involvement. The authors examine emergency responses involving stimulants between 2013 and 2020 in Massachusetts. They categorize calls in 3 classes: class 1 – any stimulant use, class 2 – problematic stimulant use in which stimulant use was associated with acute medical or behavioral issue, and class 3 – acute stimulant-related incidents in which stimulant use was the primary issue for the call. Over the study period, calls in all 3 categories steadily increased, were more likely to be among younger adults, and the callers were more frequently male. While race/ethnicity data were frequently missing, when the data were present, Hispanic/Latinx and Black non-Hispanic patients appeared to be overrepresented among stimulant-related calls. 
 
Trends in Prevalence of Cigarette Smoking Among US Adults With Major Depression or Substance Use Disorders, 2006-2019
JAMA
This cross-sectional study assessed trends in past-month prevalence of cigarette smoking among adults with vs. without past-year major depressive episode (MDE), substance use disorders (SUDs), or both. Using data from the 2006-2019 US National Surveys on Drug Use and Health, past-month self-reported cigarette smoking prevalence declined significantly among adults with MDE from 37.3% to 24.2% (average annual percent change: −3.2), adults with SUD from 46.5% to 35.8% (average annual percent change: −1.7), and adults with co-occurring MDE and SUD from 50.7% to 37.0% (annual average annual percent change of −2.1). Prevalence declined significantly for each examined subgroup but not for American Indian or Alaskan Native with either MDE or SUDs.
 
Emerging Agents of Substance Use/Misuse
Emergency Medicine Clinics of North America
In the last decade, there has been a rise in the use of novel psychoactive substances (NPS) for recreational purposes. Many of these synthetic psychoactive substances are derived or based on older substances of abuse, but because of their novel structures, they are not easily detectable by routine immunoassay urine drug screens. Clinical effects encountered in patients using these substances depend on the substance’s structure but can be unpredictable due to the effects on various receptors at varying doses. It is important for clinicians to be aware that these novel substances exist because the diagnosis is often clinical and not based on UDS. Treatment for these substances is generally supportive and aimed at the presenting signs and symptoms.
 
Dopamine Supersensitivity: A Novel Hypothesis of Opioid-Induced Neurobiological Mechanisms Underlying Opioid-Stimulant Co-use and Opioid Relapse  [Open Access]
Frontiers in Psychiatry
Stimulants are uniquely reinforcing to persons with opioid physical dependence, contribute to the acute opioid withdrawal syndrome, and could manifest as craving and/or motivation to use, prompting opioid relapse during acute and protracted withdrawal. Current research demonstrates that changes in the dopamine system occur once physical dependence to opioids develops, the chronicity of opioid exposure is associated with a severity of changes, and dopamine deficits persist long after signs of opioid withdrawal appear to have resolved.  This review discusses how dopamine supersensitivity develops soon after opioid abstinence and results in increased response to dopamine agonists that increases in magnitude as the abstinence period continues and is evident several weeks into protracted withdrawal.  
 
Psychological online interventions for problem gambling and gambling disorder – A meta-analytic approach
Journal of Psychiatric Research
In the context of the Covid-19 pandemic, this systematic review and meta-analysis investigated the effectiveness of psychological online interventions on problem gambling and gambling disorder (PGGD). Results indicate that psychological online interventions have moderate effects on PGGD in the short term. There was no indication that guided vs. unguided forms of online interventions affect the outcome. However, there is a clear trend toward unguided and even autonomous interventions which have the potential to complement or even substitute a therapist in person. Recent reviews indicate the superiority of online CBT formats compared to interventions with other theoretical backgrounds. 
Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies | Research, Methods, Statistics
JAMA Psychiatry
There has been considerable attention to the evidence showing the benefits of psychedelic- and MDMA-assisted therapy. Less is known about the associated risks, primarily psychiatric, such as mood and thought disorders that sometimes outlast the acute effects of the drug and may provoke suicidal behavior. It will be important to identify patients at higher risk, for example patients with a family history of schizophrenia or bipolar disorder; however, such patients have been excluded from most clinical trials. One consideration is the implementation of risk evaluation and management strategies (REMS) but MDMA and psilocybin are already in the public domain so alternate strategies may be needed. 
 
Implementation of a Standardized Clinical Definition of Opioid Withdrawal in the Neonate Challenges and Opportunities
JAMA
A standard clinical definition for neonatal abstinence syndrome (NAS) has been lacking for more than 45 years. The new definition of opioid withdrawal in the neonate includes 2 specific elements: in utero exposure to opioids with or without exposure to other psychotropic substances and the presence of 2 of 5 of the most common clinical signs of opioid withdrawal. A consistent clinical definition is essential in informing treatment protocols, administrative coding, surveillance, research criteria, and the spectrum of care for the mother-infant dyad. This could provide a significant shift in the way mothers and neonates with prenatal opioid exposure are identified, and represents a promising path forward for pregnant people and neonates with prenatal opioid exposure to improve their health and well-being